In the biotech industry, your breakthroughs are only as safe as your weakest digital link.
Genomics labs and clinical trial organizations handle highly sensitive data from patient identifiers to proprietary research. That makes your organization a prime target for attackers motivated by financial gain, nation-state espionage, or competitive advantage.
That’s why Single Point of Contact works with biotech firms to proactively identify vulnerabilities before hackers do. Our 24×7 SOC services, incident response expertise, and compliance consulting are specifically designed for high-risk, high-compliance environments like yours.
But detection is only half the equation. Today’s C-suite needs to think like the adversary. That’s where offensive security testing comes in and why it’s critical to your biotech data defense strategy.
What is Offensive Security Testing?
Offensive security testing simulates how real attackers would attempt to breach your environment not just to check boxes, but to truly expose how your defenses hold up under pressure.
Unlike traditional assessments that review known vulnerabilities, offensive security actively challenges assumptions by simulating actual attack behavior. In regulated, IP-driven environments like genomics labs or CROs, this can reveal blind spots your internal team or compliance auditors may never see.
Why Biotech Labs Are High-Value Targets
Attackers go where the value is and biotech labs are a goldmine.
- Intellectual property theft: Drug formulas, genome sequences, and trial methodologies are worth millions on the black market.
- Clinical data leakage: Patient PII and PHI can be sold or used in secondary fraud schemes.
- Operational disruption: Ransomware can halt lab processes, delaying FDA timelines or contract deliverables.
- Insider threats: Whether intentional or accidental, insiders often bypass technical controls unnoticed.
Even the most advanced security tools can’t fully eliminate human error, misconfigurations, or third-party exposure. Offensive testing closes that gap.
What Offensive Security Reveals in a Lab Environment
Offensive security in life sciences environments goes beyond firewalls and email filters. Here’s what it often uncovers:
- Unsegmented lab networks: Lab instruments and business systems often share the same VLAN, exposing sensitive equipment to broader risks.
- Weak third-party access controls: CROs, data partners, and cloud vendors often connect to core systems without granular permissions.
- Outdated lab firmware or unsecured APIs: Legacy equipment and custom integrations can be soft entry points into critical systems.
- Poor credential hygiene: Weak or shared credentials still exist in many internal systems, including electronic lab notebooks or LIMS platforms.
- Social engineering exposure: Phishing simulations often bypass technical safeguards through human error, especially among research teams not trained in cybersecurity awareness.
How Biotech Leaders Should Approach Offensive Testing
For C-suite executives, offensive testing isn’t about proving your team wrong it’s about protecting your people, your patients, and your pipeline.
Here’s what a smart, lab-ready testing strategy includes:
- Define data risk zones
Identify where your most sensitive IP, PHI, or trial data resides — and which systems directly or indirectly touch them. - Test like a real adversary
Simulate both internal and external threat vectors: phishing campaigns, physical access attempts, and cloud misconfigurations. - Prioritize high-impact weaknesses
Focus on what would really hurt like a ransomware attack on your sequencing cluster or IP exfiltration via a remote research login. - Integrate findings into response plans
Offensive testing is useless without a solid follow-up. Build the results into your incident response and compliance documentation. - Train technical and research teams differently
Your security team might know the risks but your lab personnel and research directors need tailored awareness training based on real findings.
A Note on Compliance: Testing is Not Optional
If your organization falls under HIPAA, GDPR, or FDA Part 11, offensive testing can demonstrate “reasonable security practices” something regulators increasingly expect.
Testing also supports:
- FDA cybersecurity readiness
- Business continuity plans for CROs
- Third-party audit preparedness for investors and partners
Ready to Think Like a Hacker?
Biotech leaders can no longer afford to be reactive. Offensive testing helps uncover what tools and dashboards can’t see and empowers your teams to build resilience before bad actors strike.
At Single Point of Contact, we support biotech firms with more than just alerts. Our 24×7 SOC monitoring, rapid incident response, and compliance-aligned testing services help life sciences companies sleep better at night knowing their breakthroughs are protected.
If you’re ready to uncover what attackers already see, contact us today.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
